scholarly article | Q13442814 |
P356 | DOI | 10.1074/JBC.M205258200 |
P698 | PubMed publication ID | 12089155 |
P2093 | author name string | Brian C Yowler | |
Cara-Lynne Schengrund | |||
Richard D Kensinger | |||
P433 | issue | 36 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | neuroblastoma | Q938205 |
P1104 | number of pages | 5 | |
P304 | page(s) | 32815-32819 | |
P577 | publication date | 2002-06-27 | |
P1433 | published in | Journal of Biological Chemistry | Q867727 |
P1476 | title | Botulinum neurotoxin A activity is dependent upon the presence of specific gangliosides in neuroblastoma cells expressing synaptotagmin I | |
P478 | volume | 277 |
Q47151324 | A Cell Line for Detection of Botulinum Neurotoxin Type B. |
Q37357100 | A neuronal cell-based botulinum neurotoxin assay for highly sensitive and specific detection of neutralizing serum antibodies |
Q35669634 | An in vitro and in vivo disconnect uncovered through high-throughput identification of botulinum neurotoxin A antagonists. |
Q33869062 | Botulinum neurotoxin D uses synaptic vesicle protein SV2 and gangliosides as receptors |
Q28485303 | Botulinum neurotoxin serotype A specific cell-based potency assay to replace the mouse bioassay |
Q36511574 | Botulinum neurotoxin structure, engineering, and novel cellular trafficking and targeting |
Q34583087 | Botulinum neurotoxin subtype A2 enters neuronal cells faster than subtype A1 |
Q38224215 | Botulinum neurotoxins: genetic, structural and mechanistic insights. |
Q39039170 | Botulinum protease-cleaved SNARE fragments induce cytotoxicity in neuroblastoma cells |
Q34995583 | Capsaicin protects mouse neuromuscular junctions from the neuroparalytic effects of botulinum neurotoxin a |
Q40265665 | Characterization of Clostridial botulinum neurotoxin channels in neuroblastoma cells |
Q82643022 | Comparison of the primary rat spinal cord cell (RSC) assay and the mouse bioassay for botulinum neurotoxin type A potency determination |
Q27651618 | Crystal Structure of Botulinum Neurotoxin Type A in Complex with the Cell Surface Co-Receptor GT1b—Insight into the Toxin–Neuron Interaction |
Q92690319 | Crystal structure of botulinum neurotoxin subtype A3 cell binding domain in complex with GD1a co-receptor ganglioside |
Q36389297 | Designer probiotics for prevention of enteric infections. |
Q79479284 | Effect of nicking the C-terminal region of the Clostridium botulinum serotype D neurotoxin heavy chain on its toxicity and molecular properties |
Q26859917 | Emerging opportunities for serotypes of botulinum neurotoxins |
Q36611014 | Entering neurons: botulinum toxins and synaptic vesicle recycling |
Q40442566 | Entry of Botulinum Neurotoxin Subtypes A1 and A2 into Neurons |
Q34702285 | Evidence That Botulinum Toxin Receptors on Epithelial Cells and Neuronal Cells Are Not Identical: Implications for Development of a Non-Neurotropic Vaccine |
Q48462023 | Expression and function of SNAP-25 as a universal SNARE component in GABAergic neurons. |
Q27656415 | Gangliosides as High Affinity Receptors for Tetanus Neurotoxin |
Q35932883 | Glycosphingolipids-sweets for botulinum neurotoxin |
Q27655649 | Glycosylated SV2 and Gangliosides as Dual Receptors for Botulinum Neurotoxin Serotype F |
Q36992893 | Glycosylated SV2A and SV2B mediate the entry of botulinum neurotoxin E into neurons. |
Q37274652 | Identification and biochemical characterization of small-molecule inhibitors of Clostridium botulinum neurotoxin serotype A |
Q34733600 | Identification of fibroblast growth factor receptor 3 (FGFR3) as a protein receptor for botulinum neurotoxin serotype A (BoNT/A). |
Q84743055 | Low pH-induced pore formation by the T domain of botulinum toxin type A is dependent upon NaCl concentration |
Q44555884 | Mode of action of botulinum neurotoxin: pathological, cellular and molecular aspect |
Q36364296 | Model for studying Clostridium botulinum neurotoxin using differentiated motor neuron-like NG108-15 cells |
Q38080382 | Molecular dissection of botulinum neurotoxin reveals interdomain chaperone function |
Q89583750 | Non-toxic fragment of botulinum neurotoxin type A and monomethyl auristatin E conjugate for targeted therapy for neuroendocrine tumors |
Q36818335 | Progress in cell based assays for botulinum neurotoxin detection |
Q35772134 | Recent developments in cell-based assays and stem cell technologies for botulinum neurotoxin research and drug discovery |
Q37408530 | Receptor and substrate interactions of clostridial neurotoxins |
Q37843686 | Receptor mimicry as novel therapeutic treatment for biothreat agents |
Q38696776 | SiMa Cells for a Serotype Specific and Sensitive Cell-Based Neutralization Test for Botulinum Toxin A and E. |
Q110866263 | Sialic acid-containing glycolipids mediate binding and viral entry of SARS-CoV-2 |
Q39157207 | Stapling of the botulinum type A protease to growth factors and neuropeptides allows selective targeting of neuroendocrine cells |
Q27643302 | Structural basis of cell surface receptor recognition by botulinum neurotoxin B |
Q27677003 | Structural insights into the functional role of the Hcn sub-domain of the receptor-binding domain of the botulinum neurotoxin mosaic serotype C/D |
Q35187559 | The C-terminal heavy-chain domain of botulinum neurotoxin a is not the only site that binds neurons, as the N-terminal heavy-chain domain also plays a very active role in toxin-cell binding and interactions |
Q36085668 | The evolving field of biodefence: therapeutic developments and diagnostics |
Q28609177 | The journey of tetanus and botulinum neurotoxins in neurons |
Q57157766 | Variability of Botulinum Toxins: Challenges and Opportunities for the Future |
Q57808978 | Variations in the Botulinum Neurotoxin Binding Domain and the Potential for Novel Therapeutics |
Q34516235 | Weak glycolipid binding of a microdomain-tracer peptide correlates with aggregation and slow diffusion on cell membranes |
Q61797224 | Why Are Botulinum Neurotoxin-Producing Bacteria So Diverse and Botulinum Neurotoxins So Toxic? |
Search more.